Tris trial is registered with FDA with number: NCT01729663. The sponsor of the trial is Laboratorio Pablo Cassará S.R.L. and it is looking for 108 volunteers for the current phase.
Official trial title:
Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients